Last reviewed · How we verify
NCT07223411
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
trial testing Fianlimab + Cemiplimab in Locally Advanced Melanoma in 20 participants. Currently enrolling.
1 November 2028
Quick facts
| Lead sponsor | John Kirkwood |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 19 November 2025 |
| Primary completion | 1 November 2028 |
| Estimated completion | 1 November 2031 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fianlimab + Cemiplimab — full drug profile →
- Relatlimab + Nivolumab
Conditions studied
- Locally Advanced Melanoma — all drugs for Locally Advanced Melanoma →
Sponsor
John Kirkwood — full company profile →
Who can join
18 and older, any sex, with Locally Advanced Melanoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07223411
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Locally Advanced Melanoma
Currently open trials in the same condition.
- NCT06066138 — A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing · Phase 1 · recruiting
- NCT05176470 — Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients · Phase 1 · active not recruiting
- NCT05269381 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT04771520 — Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors · Phase 2 · recruiting
- NCT06075524 — Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types · recruiting
Other John Kirkwood trials
Trials by the same sponsor.
- NCT04688658 — Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma · Phase 1, PHASE2 · terminated
- NCT03743766 — Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Imm · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07223411 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by John Kirkwood
- Last refreshed: 26 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07223411.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing